Milestone Pharmaceuticals ( (MIST) ) has released its Q2 earnings. Here is a breakdown of the information Milestone Pharmaceuticals presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focusing on the development and commercialization of cardiovascular medicines, particularly its lead product candidate, etripamil, a rapid-onset nasal spray designed to treat various cardiovascular conditions.
In its latest earnings report for the quarter ended June 30, 2025, Milestone Pharmaceuticals reported no revenue, reflecting its current focus on research and development activities. The company continues to invest heavily in its lead product candidate, etripamil, which is undergoing clinical trials for the treatment of paroxysmal supraventricular tachycardia and other cardiovascular indications.
Key financial metrics from the report indicate a net loss of $12.97 million for the quarter, compared to a loss of $9.36 million in the same period last year. Operating expenses increased significantly, driven by higher research and development costs and commercial activities. The company’s cash and cash equivalents rose to $42.5 million, supported by strategic financing activities, despite a shareholders’ deficit of $17.7 million.
Looking forward, Milestone Pharmaceuticals remains committed to advancing the clinical development of etripamil. The management is optimistic about securing regulatory approvals and potential commercialization, which could significantly impact the company’s financial trajectory. The company is also exploring strategic collaborations and funding opportunities to support its ongoing operations and future growth.